Search research articles
Contact Us
Filters
Showing results (181-190 of 317) with videos related to
Page
of 32
Sort By:
Future Oncology (London, England)
|
March 31, 2026
Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H Miller, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 25, 2025
Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial
L L Hoeijmakers, E A Rozeman, M Lopez-Yurda, et al.
Cell Reports
|
June 21, 2016
BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts
Kristel Kemper, Oscar Krijgsman, Xiangjun Kong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 22, 2019
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers
S Trebeschi, S G Drago, N J Birkbak, et al.
JCI Insight
|
November 8, 2024
Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma
Joris L Vos, Joleen Jh Traets, Xiaohang Qiao, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 18, 2021
Survival of stage IV melanoma in Belgium and the Netherlands
K P M Suijkerbuijk, J B A G Haanen, M J Boers-Sonderen, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
April 20, 2023
Health-state utilities in long-term advanced melanoma survivors comparable with the general population
M D Egeler, L V van de Poll-Franse, R Tissier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 30, 2019
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Y J L Jansen, E A Rozeman, R Mason, et al.
Annals of Surgery
|
April 12, 2021
Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single-arm, Open-label Phase II Trial
Stéphanie A Blankenstein, Maartje W Rohaan, Willem Martin C Klop, et al.
Cancers
|
November 25, 2023
Time Trends in the Treatment and Survival of 5036 Uveal Melanoma Patients in The Netherlands over a 30-Year Period
Thaïs M L Tong, Esther Bastiaannet, Frank M Speetjens, et al.
Page
of 32
Search research articles
Search
Showing results (181-190 of 317) with videos related to
Sort By:
Page
of 32
Future Oncology (London, England)
|
March 31, 2026
Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H Miller, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 25, 2025
Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial
L L Hoeijmakers, E A Rozeman, M Lopez-Yurda, et al.
Cell Reports
|
June 21, 2016
BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts
Kristel Kemper, Oscar Krijgsman, Xiangjun Kong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 22, 2019
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers
S Trebeschi, S G Drago, N J Birkbak, et al.
JCI Insight
|
November 8, 2024
Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma
Joris L Vos, Joleen Jh Traets, Xiaohang Qiao, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 18, 2021
Survival of stage IV melanoma in Belgium and the Netherlands
K P M Suijkerbuijk, J B A G Haanen, M J Boers-Sonderen, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
April 20, 2023
Health-state utilities in long-term advanced melanoma survivors comparable with the general population
M D Egeler, L V van de Poll-Franse, R Tissier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 30, 2019
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Y J L Jansen, E A Rozeman, R Mason, et al.
Annals of Surgery
|
April 12, 2021
Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single-arm, Open-label Phase II Trial
Stéphanie A Blankenstein, Maartje W Rohaan, Willem Martin C Klop, et al.
Cancers
|
November 25, 2023
Time Trends in the Treatment and Survival of 5036 Uveal Melanoma Patients in The Netherlands over a 30-Year Period
Thaïs M L Tong, Esther Bastiaannet, Frank M Speetjens, et al.
Page
of 32